Pfizer Inc.
METHODS OF TREATING CANCER USING COMBINATION THERAPY
Last updated:
Abstract:
The present application is directed to therapeutic regimens and methods of treating cancer, with the regimens and methods comprising administering to the subject a programmed death-ligand 1 (PD-L1) inhibitor and a recombinant vesicular stomatitis virus that has been engineered to expresses interferon beta (VSV-IFN.beta.-NIS).
Status:
Application
Type:
Utility
Filling date:
21 Jun 2019
Issue date:
19 Aug 2021